| ASP2998 for carcinoma, transitional cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ASP2998 + Carboplatin + ENFORTUMAB VEDOTIN + PEMBROLIZUMAB for carcinoma, transitional cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Avelumab for carcinoma, transitional cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Enfortumab vedotin + pembrolizumab for carcinoma, transitional cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ERDAFITINIB + Carboplatin + CETRELIMAB + CISPLATIN for carcinoma, transitional cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Erdafitinib + cetrelimab for carcinoma, transitional cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Home Health Encounter + Patient Monitoring + Questionnaire Administration + NIVOLUMAB for carcinoma, transitional cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Izalontamab Brengitecan for carcinoma, transitional cell | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Laboratory Biomarker Analysis + Pharmacological Study + Eribulin Mesylate for carcinoma, transitional cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for carcinoma, transitional cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for carcinoma, transitional cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| n-dodecyl-B-D-maltoside + Cretostimogene Grenadenorepvec for carcinoma, transitional cell | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Nivolumab for carcinoma, transitional cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Pemetrexed + AVELUMAB for carcinoma, transitional cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| PF-08634404 for carcinoma, transitional cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| PF-08634404 + ENFORTUMAB VEDOTIN for carcinoma, transitional cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Reproductive organ sparing radical cystectomy for carcinoma, transitional cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sacituzumab tirumotecan for carcinoma, transitional cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| SI-B003 + Izalontamab Brengitecan for carcinoma, transitional cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Spartalizumab for carcinoma, transitional cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tislelizumab for carcinoma, transitional cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| TTP-ICG fluorescent probe for carcinoma, transitional cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| TYRA-300 for carcinoma, transitional cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|